Prognostic role of the systemic immune-inflammation in patients with non-small cell lung cancer: a meta-analysis

OBJECTIVE: To explore the prognostic value of systemic immune-inflammation in assessing patients with non-small cell lung cancer. Methods: The meta-analysis was conducted from May to July 2023, and comprised a comprehensive search PubMed, Excerpta Medica Database and Cochrane Library databases up to March 21, 2023, for relevant peer-reviewed articles evaluating the prognostic value of systemic immune-inflammation in patients with non-small cell lung cancer. Hazard ratio and 95% confidence interval were calculated to assess systemic immune-inflammation's relationship with overall survival and progression-free survival. Data was analysed using STATA 17.0. RESULTS: Of the 135 studies initially identified, 32(23.7%) were analysed in detail, involving 12,040 patients. Increased systemic immune-inflammation was significantly associated with poor overall survival (hazard ratio: 1.31; 95% confidence interval: 1.21-1.41; p